| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-02-20 | Selexis (Switzerland) Amgen (USA) | licensing R&D |
||||
| 2013-02-20 | 4SC Discovery (Germany) BioNTech (Germany) | new small molecule anti-cancer drugs for defined therapeutic targets | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-02-20 | ProBioGen (Germany) undisclosed global pharma company | GlymaxX® Antibody Glyco-Engineering technology | licensing |
Licensing agreement | ||
| 2013-02-20 | LFB Biotechnologies, Laboratoire français du fractionnement des biotechnologies (France) Thallion Pharmaceuticals (Canada) | Shigamabs® program | development |
Infectious diseases | Development agreement | |
| 2013-02-19 | Sobi - Swedish Orphan Biovirum (Sweden) Savient Pharmaceuticals (USA) | Kineret® (anakinra) | rheumatoid arthritis neonatal-onset multisystem inflammatory disease (NOMID) |
promotion | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Rare diseases | |
| 2013-02-18 | Roche (Switzerland) Chiasma (USA - Israel) | Octreolin® | acromegaly neuroendocrine tumors |
development |
Rare diseases - Hormonal diseases - Endocrine diseases - | |
| 2013-02-18 | AbCheck (Czech Republic) U3 Pharma - a Daiichi Sankyo company (Germany - Japan) | antibodies against an undisclosed number of U3 Pharma targets | R&D | Undisclosed | ||
| 2013-02-14 | Mylan (USA - PA) Biocon (India) | biosimilar products, insulin analog products | type 1 diabetes, type 2 diabetes | development - commercialisation | Metabolic diseases | Development agreement |
| 2013-02-12 | Vivalis (France) undisclosed North American animal health vaccine company | EB66® cell line | licensing | Veterinary medicine | ||
| 2013-02-12 | Genentech, a member of Roche group (USA - Switzerland) RQx Pharmaceuticals (USA) | novel drug compounds for an undisclosed target | R&D | Infectious diseases | ||
| 2013-02-12 | AstraZeneca (UK) Petrov Institute of Oncology (Russia) | identification of genetic mutations in cancer patients | R&D | Cancer - Oncology | ||
| 2013-02-12 | Dako (Denmark) Pfizer (USA - NY) | companion diagnostics | collaboration |
Collaboration agreement | ||
| 2013-02-11 | Icon (Ireland) DIA | webinar projects on oncology, technology, biomarkers and late phase development | collaboration | Cancer - Oncology | ||
| 2013-02-11 | GSK (UK) Vanderbilt University (USA -TN) | novel therapies for severe obesity (positive allosteric modulators or PAMs that increase MC4-R activity) | severe obesity | development |
Metabolic diseases - Endocrine diseases - Hormonal diseases | Development agreement |
| 2013-02-08 | Pergamum (Sweden) Cadila Pharmaceuticals (India) | therapeutic peptide | development | Infectious diseases | ||
| 2013-02-06 | Inserm Transfert (France) MassBio (USA) | collaboration |
Collaboration agreement | |||
| 2013-02-06 | Summit (UK) The Foundation to Eradicate Duchenne Muscular Dystrophy - Children\'s National Medical Center (USA) | utrophin biomarkers | Duchenne Muscular Dystrophy (DMD) | R&D |
Genetic diseases - Neuromuscular diseases - Rare diseases | R&D agreement |
| 2013-02-06 | Antitope (UK) Eden Biodesign (UK) | therapeutic antibodies | R&D |
R&D agreement | ||
| 2013-02-05 | Vivalis (France) Fatro (Italy) | EB66® cell line | licensing |
Veterinary Medicine | Licensing agreement | |
| 2013-02-04 | Karolinska Development (Sweden) Mayo Clinic Venture (USA) | collaboration |
Collaboration agreement |
